# Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

> **NCT03342352** · PHASE3 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Epacadostat
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Cetuximab
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT03342352
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-15
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-04-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was cancelled prior to enrolling any patients.
- **Last updated:** 2019-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03342352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03342352, "Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03342352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*